This review discusses the mechanism of action and evidence of benefit for newer antiplatelet agents across various clinical scenarios.
Answers are grounded in this paper and cite their sources.
Updates clinicians on recent antiplatelet advances; leaves open optimal use pending further trials.
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
No takes yet. Share an insight, caveat, or question.
AH Gershlick (2000) conducted a review in Coronary artery disease and acute coronary syndromes. Antiplatelet therapy (aspirin, ADP receptor inhibitors, GPIIb-IIIa antagonists) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: